$Bob's and Jbem's Bitchin' Bios

[buckiii2]

CorMedix to Present at Biotech Showcase™ 2016

CorMedix to Present at Biotech Showcase™ 2016
PR CorMedix Inc.



CorMedix, Inc. Earnings Analysis: Q3, 2015 By the Numbers Capital Cube q 19 days ago
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online 22 days ago
More

BEDMINSTER, N.J., Jan. 6, 2016 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the Company will present at the Biotech Showcase™ 2016, taking place in San Francisco, CA, on January 11–13, 2016.

Randy Milby, Chief Executive Officer of CorMedix, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Meetings with management may also be scheduled outside of Biotech Showcase by contacting CorMedix's Investor Relations Maureen McEnroe; [phone].

Event: Biotech Showcase™ 2016
Date: Wednesday, January 13, 2016
Time: 9:30 a.m. (Pacific Time)
Location: Parc 55 San Francisco

A live audio webcast of the presentation will be available on the Investors section of the CorMedix website at www.cormedix.com. The webcast will be archived and available for replay for 90 days.

About CorMedix Inc.
CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. CorMedix initiated a Phase III clinical study in the United States in December 2015. CorMedix enjoys a solid patent portfolio, and expanding product pipeline, and the important benefits of Fast Track status as well as a Qualified Infectious Disease Product designation. The initial and subsequent products under development will address significant unmet needs in the United States and in the rest of the world. For more information visit:www.cormedix.com.

For Investors & Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: [e-mail]; [phone]
Janine McCargo: [e-mail]; [phone]
Webcast Link - Weds 12:30 eastern Biotech Showcase San Francisco. 9:30 am eastern


Link for CorMedix Inc.:

http://edge.media-server.com/m/p/5c2n4vsd